TZTugba Mandal Zi̇rEk

Tugba Mandal Zi̇rEk

*This is an algorithmically generated author record based on publicly available information.

Tugba Mandal Zi̇rEk has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Intensive care utilization in COPD and advanced-stage lung cancer

    by Gülfidan Aras, Tuğba Mandal Zirek, Zehra Dilek Kanmaz, Fatma Tokgöz Akyıl

    Aims: Patients with terminal lung cancer and COPD frequently require intensive care unit (ICU) care, yet survival benefits remain uncertain. We evaluated ICU outcomes and the impact of palliative care integration in a tertiary chest hospital. Methods: A retrospective review included 731 patients transferred to ICUs between 2013–2019. Outcomes were compared before and after the establishment of a palliative care unit in 2016. Results: Lung cancer accounted for 33.5% of cases and COPD for 66.5%. ICU mortality was 91.7% in cancer and 82% in COPD, with only 10.5% overall survival. Post-discharge survival remained poor, as 4.1% died shortly after ICU transfer. Mean ICU stays were 7.8 and 11.6 days, respectively. Palliative care availability did not significantly change ICU referral rates. Conclusion: ICU treatment for end-stage COPD and lung cancer is associated with very limited survival. Effective palliative care integration and structured end-of-life decision-making are urgently needed to optimize ICU use.

  • DO LATENT TUBERCULOSIS AND AGE IMPACT THE POST-COVID-19 EXPERIENCE?

    by Zehra Dilek Kanmaz, Tuğba MANDAL ZİREK, Gülfidan Aras, Esin Tuncay

    Background: There is not enough information about the long-term effects of COVID-19 infection in those who have recovered. According to epidemiological studies, COVID-19 progresses less severely in countries where the Bacillus Calmette-Guerin vaccine is regularly applied than in those where it is not. The purified protein derivative of tuberculin is an indicator of the Bacillus Calmette-Guerin vaccine’s protective effectiveness against latent tuberculosis. In our study, we aimed to investigate the relationship between latent tuberculosisand the permanent effects of COVID-19.Our objective was to analyze the long-term relationship between latent tuberculosisand COVID-19. Materials and Method: We included all clinical, laboratory, and radiological baseline data of patients who were hospitalised for COVID-19 pneumonia between 2020 and 2021 during the pandemic in our study and compared them with data from six months later. Results: Although there was no statistically significant correlation between purified protein derivative of tuberculin positivity and the long-term effects of COVID-19 (p = 0.084), age exhibited a statistically significant relationship with the presence of post-COVID-19 sequelae (p = 0.004). Patients with chronic pulmonary disease displayed a significantly greater percentage of symptoms (p=0.005). Conclusion: We could not find any relationship between purified protein derivative of -tuberculin latent tuberculosis infection and long COVID-19 symptoms. We observed sequelae lesions more frequently in the follow-up of elderly patients. Post-COVID-19 symptoms were more common in patients with chronic lung disease. Thus, it is recommended to prioritise radiological and clinical follow-up in elderly patients and those with chronic lung conditions. Keywords: Post-Acute COVID-19 Syndrome, Latent Tuberculosis, COVID-19, Aged.

  • Non-metastatic Squamous Cell Lung Carcinoma: A rare case report

    by Hülya Abali, Tugba Mandal Zi̇rEk, Fatma Tokgöz Akyil, Zehra Büşra Özbolat, Aslı KOCAOĞLU, Kübra Gül Kilinçarslan, Seda Tural Önür

    Central and peripheral types of squamous cell carcinoma (SQCC) are classified in different categories due to different clinical-pathological features. Peripheral SQCC, according to histological pattern; it is classified into three subgroups as alveolar space-filling type, expanding type and combined type. Of these three subtypes, alveolar space-filling neither causes lymphatic vessel invasion nor lymph node metastasis and has the best prognosis. Herein, we present a rare case of squamous cell carcinoma that did not metastasize at two and a half years years from initial diagnosis.